Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on treatment with first-line DMTS or no current MS treatment..
Epistemonikos ID: d3d0e5664682b77a93a25236b056af3aed0f0343
First added on: Mar 12, 2021